single dose of

Phase 3Small molecule

Boehringer Ingelheim

single dose of is one of 159 small molecule programs targeting Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

158

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

MelanomaActive, not recruiting

Ovarian CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Small Cell Lung CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Fabhalta

Regeneron

Phase 3

3 2

Imjudo

AstraZeneca

Phase 3

2 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

10 4

Incomplete Freund's Adjuvant

EEastern Cooperative Oncology Group

Phase 3

20 5

single dose of

Boehringer Ingelheim

Phase 3

1 6

Tumor Necrosis Factor

NNational Cancer Institute (NCI)

Phase 3

1 7

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 8

GM2-KLH Vaccine

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Phase 3

1 9

Allovectin-7

VVical

Phase 3

3 10

Intron a

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Small Cell Lung Carcinoma (SCLC)

NCT05990738

Phase 2Recruiting

Lung Cancer

NCT05568212

Q3 2034

Phase 3Recruiting

Melanoma

NCT06264180

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01809262·36 enrolled

Ovarian Cancer1 trial

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02282020·266 enrolled

Melanoma1 trial

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

Recruiting·RReplimune Inc.·Phase 3·NCT06264180·400 enrolled

Lung Cancer1 trial

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Recruiting·FFondazione Ricerca Traslazionale·Phase 2·NCT05568212·176 enrolled

Tics1 trial

Safety, Pharmacodynamics, and Pharmacokinetics of BIBT 1011 BS in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02182037·56 enrolled

1 more indication

Small Cell Lung Carcinoma (SCLC)1 trial

DAREON™-9: A Phase Ib Open-label Dose Escalation and Dose Confirmation Safety Study of Intravenous BI 764532 in Combination With a Single Agent Chemotherapy for the Treatment of Patients With Relapsed/Refractory Small Cell Lung Cancer After Platinum-based Chemotherapy

Active, not recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05990738·69 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for single dose of. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — single dose of compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for single dose of. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Boehringer Ingelheim

single dose of

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2034

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

Ovarian Cancer1 trial

Melanoma1 trial

Lung Cancer1 trial

Tics1 trial

Small Cell Lung Carcinoma (SCLC)1 trial

References

Drug Info

Quick Facts

Related News